ResearcherInsermActive in the last 2 years

Éric Deutsch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8223-3697; OpenAlex author ID A5014829112. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gilles Colin · 1 shared paper, 2026 · strength 0.39
- Paper Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer. DOI 10.1038/s41575-026-01250-4 ↗
Lorenzo Galluzzi · 1 shared paper, 2026 · strength 0.39
- Paper Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer. DOI 10.1038/s41575-026-01250-4 ↗
Pierre Foidart · 1 shared paper, 2026 · strength 0.39
- Paper Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer. DOI 10.1038/s41575-026-01250-4 ↗
F. Huguet · 1 shared paper, 2012 · strength 0.04
- Paper FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning. DOI 10.1097/mpa.0b013e3182496e90 ↗
Antonin Lévy · 1 shared paper, 2012 · strength 0.04
- Paper FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning. DOI 10.1097/mpa.0b013e3182496e90 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.